Xenon MRI scan to find signs of blood vessel changes in lung disease
Tests inhaled xenon MRI imaging in adults with lung diseases affecting blood vessels.
Plain-language title generated from the registry record
Registry title: Pulmonary Hypertension SOLAR
Key facts
- Where
- Durham, United StatesSee the site
- Phase
- Phase 2
Where in United States
- Duke University Medical CenterDurham, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bastiaan Driehuys
- Trial code
- NCT04778046
- Record updated
- 24 February 2026
- Original description
The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signature has been shown in previous studies. Past studies have lacked a pathologic "ground truth" correlate of these signatures, which could be provided by comparing them with the pathology of lung explant tissue from patients who have undergone a lung transplant. This signature could be validated in a cohort of patients with Group 3 PH in future studies.Read full original descriptionShow less
Defining a Noninvasive Signature for Pulmonary Vascular Remodeling in Group 3 PH
The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signature has been shown in previous studies. Past studies have lacked a pathologic "ground truth" correlate of these signatures, which could be provided by comparing them with the pathology of lung explant tissue from patients who have undergone a lung transplant. This signature could be validated in a cohort of patients with Group 3 PH in future studies.
Inclusion: Age ≥ 18 years' old; Be on the lung transplant waiting list at Duke University Medical Center; PH as defined by RHC - mPAP > 20 mmHg, PVR > 3 WU, PCWP < 15 mmHg; Groups defined as:; PAH: Clinical diagnosis of PAH (Group 1 PH) in the absence of severe chronic lung disease, left heart disease, chronic thromboembolism, sarcoidosis, sickle cell disease, or other causes of non-Group 1 PH; COPD-noPH: Clinical diagnosis of COPD in the absence of precapillary PH; COPD-PH: Clinical diagnosis of COPD with precapillary PH; IPF-noPH: Clinical diagnosis of IPF in the absence of precapillary PH; IPF-PH: Clinical diagnosis of IPF with precapillary PH; Willing and able to give informed consent and adhere to visit/protocol schedules (consent must be given before any study procedures are performed).
Exclusion: Active cancer; Liver disease (Childs-Pugh class C); Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to lie supine); Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements; Moderate to severe heart disease (LVEF < 45% or severe LV Hypertrophy); Sarcoidosis; Sickle cell anemia; Prisoners and pregnant women will not be approached for the study; Inability to obtain consent.